Indian Drug Makers Advised To Focus On Brazil, Japan, Russia For Growth
This article was originally published in PharmAsia News
An official of IMS Health told Indian drug makers they need to focus on Japan, Russia and Brazil as the fastest-growing emerging markets for pharmaceuticals as U.S. blockbuster drugs lose their patent protections.
You may also be interested in...
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.